Tyrosine kinase inhibition and chemotherapy;Tirozin kinaz i̇nhibisyonu ve kemoterapi

SENDROM

Volumn 16, Issue 4, 2004, Pages 45-48

  Zeren, Tamer ^a   Ekerbiçer, Nuran ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SURVIVAL; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; UNITED STATES;

EID: 2442508823     PISSN: 10165134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wood WC. Progress from clinical trials on breast cancer. Cancer, 74: 2606-2609, 1994.
2. Marshall E. Search for a killer: focus shifts from fat to hornones. Science, 259: 618-621, 1993.
3. Somlo G, Doroshow JH, Forman SH, Leong LA, Margolin KA, Morgan RJ, Raschoko JW, Akkman SA, Ahn C, Nagasawa S: High-dose doxorubucin, etoposide and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer, 73: 1678-1685, 1994.
4. American Cancer Society. Cancer Fact & Figures, New York: 10, 1994.
5. Carpenter G., Cohen S. Epidermal Growth Factor. Journal of Biological Chemistry, 265: 7709-7712, 1990.
6. Harold K, William JM: The role of the EGF receptor family in mammary tumorigenesis and metastasis, Experimental Cell Research, 253: 78-87, 1999.
7. Stern DF: Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Research, 2: 176-183, 2000.
8. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 19: 183-232, 1995.
9. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of EGF-R in human breast cancer: A review on 5232 patients, 13(1): 3-17, 1992.
10. Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Research and Treatment, 52(1-3): 43-53, 1998.
11. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science, 267: 1782-1788, 1995.
12. Peterson G, Barnes S: Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochemical & Biophysical Research Communications, 179(1): 661-667, 1991.
13. Peterson G, Barnes S: Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth and Differentiation, 7(10): 1345-1351, 1996.
14. Uckun FM, Narla RK, Jun X, Zeren T, Vencatachalam T, Waddick KG, Rostostev A, Myers DE: Cytotoxic activity of epidermal growth factor - genistein against breast cancer cells. Clinical Cancer Research, 4: 901-912, 1998.
15. Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom L, Gunther R, Evans W: In-vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clinical Cancer Research, 4: 1125-1134, 1998.
16. Hoffman R: Potent inhibition of breast cancer cell lines by the isoflavonoid kievitone: comparison with genistein. Biochemical & Biophysical Research Communications, 211(2): 600-606, 1995.
17. Schultze-Mosgau MH, Dale IL, Gant TW, Chipman JK, Kerr DJ, Gescher A: Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. European Journal of Cancer, 34: 1425-1431, 1998.
18. Tolcher AW: Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. Oncologist, 6(3): 40-44, 2001.